BioMelbourne Network
Progressing BioIndustry

News and Opinions

9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17

2011

October

Burnet's Malaria Researchers Among Australia's Best at Conference

  4 October 2011. Australia’s best malaria researchers have come together for the two-day Malaria in Melbourne (MiM) Conference, which focuses on early-career researchers and their latest work. ? Melbourne has more than 40 malaria labs and a lot of the world-first research into the devastating disease comes out of Melbourne-based institutes. ? MiM is an opportunity for researchers to exp... read more…
September

Patrys Delivers Positive 10 Year Data

    Melbourne, Australia; 27 September, 2011: Patrys Limited (ASX: PAB; "the Company"), today announced positive results from a follow-up of gastric cancer patients who were treated with anti-cancer compound PAT-SC1. • Significant survival benefit for PAT-SC1 treated patients • 10 year survival data now available PAT-SC1 was the first of the Patrys’ IgM antibodies to be used in a clini... read more…

Mesoblast and Lonza Establish Strategic Global Manufacturing Alliance

27 September 2011, Melbourne, Australia and Basel, Switzerland 26 September 2011 - Global regenerative medicine company Mesoblast Limited (ASX: MSB) and Lonza Group (SWS: LONN), a world leader in biologic manufacturing, today announced that they have entered into a strategic alliance for clinical and long-term commercial production of Mesoblast’s off-the-shelf (allogeneic) adult stem cell produ... read more…

Zita peach Appointed NED to Starpharma

26 September 2011. Melbourne, Australia : Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) has today announced the appointment of Ms Zita Peach as a Non-Executive Director.   Zita has more than 20 years of commercial experience in the pharmaceutical industry, particularly in marketing and business development, working for major industry players such as CSL Limited and Merck Sharp & Dohm... read more…

Phosphagenics Ready to Commence Pivotal Oxycodone Clinical Trials

  19 September 2011, Melbourne, Australia: Australian drug delivery technology company Phosphagenics Limited (ASX: POH, OTCQX: PPGNY) has, in collaboration with 3M, completed the optimisation of the TPM/oxycodone patch. This milestone clears the way for the company to commence its pivotal oxycodone clinical trials. Phosphagenics has previously shown that the prototype patches developed in-... read more…

Phosphagenics Signs Development Deal With Global Cosmetics Company

  14 September 2011, Melbourne, Australia: Melbourne drug delivery technology company Phosphagenics Limited (ASX: POH) has entered into an agreement with a leading global cosmetic and dermatology company to conduct a human study on a new cosmetic product incorporating its TPM® platform delivery system. Phosphagenics’ CEO, Dr Esra Ogru, said the partnership with another leading cosmetic, hig... read more…

Clinuvel Completes Scenesse Pre-Clinical Program

4 September 2011Clinuvel says it has completed its pre-clinical program for its ultra-violet light protection drug Scenesse or afamelanotide.Clinuvel said completing the program was “an important regulatory milestone” for filing the marketing authorization application to the European Medicines Agency for the orphan disease erythropoietic protoporphyria.The company said the data from the four pr... read more…

Acrux Loses Founder, Director Prof Barrie Finnin

4 September 2011Acrux says co-founder Prof Barrie Finnin has retired as a director after 12 years’ service to the company. Acrux said Prof Finnin was a co-inventor of its transdermal drug delivery technology and he played an integral role in developing the core technology and the company’s corporate growth. Acrux said it would appoint a suitably qualified non-executive director to replace Pro... read more…

R&D Tax Incentive All Set To Support Australian Businesses

Friday, 2 September 2011. Information sessions, held across Australia in September and October, will help businesses learn how to access and best use the new R&D Tax Incentive to drive the development of new ideas, products and processes. Encouraging people to attend, Innovation Minister Senator Kim Carr, said the R&D Tax Incentive, as the program will be now known, will support and reward the... read more…

Medicines Development places first Development Manager at Virax Holdings Ltd

31st August, 2011 - Medicines Development is pleased to announce that Charlotte Mulder has completed its rigorous Development Manager Training Program and has been successfully placed at Virax Holdings Ltd as a Development Manager. Charlotte is Medicines Development's first trainee and placement under its Development Manager training and placement initiative supported by the Victorian Governmen... read more…